Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.regeneron.com
Regeneron Pharmaceuticals Inc. News Releases
Get the latest updates from Regeneron Pharmaceuticals Inc. News Releases directly as they happen.
Follow now 264 followers
Latest posts
Last updated 8 days ago
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
8 days ago
Positive opinion based on results of Phase 3 C-POST trial that show...
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
10 days ago
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights...
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
13 days ago
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including...
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
17 days ago
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced...
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
25 days ago
TARRYTOWN, N.Y. , Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc...
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
29 days ago
FDA approval extends the indication of Evkeeza to treat younger patients with...
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
about 1 month ago
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent...
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
about 1 month ago
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by...
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
about 1 month ago
Complete 26-week results further demonstrate that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped...
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
about 1 month ago
FOP is a disease in which muscles, tendons and ligaments are progressively...
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
about 2 months ago
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates...
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
about 2 months ago
In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody...